An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

BACKGROUND: Over half of colorectal cancers (CRCs) are hard-wired to RAS/RAF/MEK/ERK pathway oncogenic signaling. However, the promise of targeted therapeutic inhibitors, has been tempered by disappointing clinical activity, likely due to complex resistance mechanisms that are not well understood. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Mingli, Davis, Thomas B., Pflieger, Lance, Nebozhyn, Michael V., Loboda, Andrey, Wang, Heiman, Schell, Michael J., Thota, Ramya, Pledger, W. Jack, Yeatman, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908604/
https://www.ncbi.nlm.nih.gov/pubmed/35272617
http://dx.doi.org/10.1186/s12885-022-09344-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908604/
https://www.ncbi.nlm.nih.gov/pubmed/35272617
http://dx.doi.org/10.1186/s12885-022-09344-3

Ejemplares similares